Navigation Links
Sunesis in Medical News

Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs

NEW YORK, Sept. 17 /PRNewswire/ -- ExL Pharma is pleased to announce three Clinical Data Focused conferences which cover many of the leading issues that are impacting the pharmaceutical industry today. These events offer educational and networking opportunities for Clinical, R&D, Regulatory an...

Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors

...ANCISCO, Calif., July 27 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...ent. "We are pleased to have Helen join the sunesis Board of Directors," said Daniel Swisher, Sunesis'... track record and commercial insights will benefit sunesis significantly." Ms. Kim is currently a Dire...

Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec

...ANCISCO, Calif., July 13 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar... term of this collaboration ended in June of 2008. sunesis retains an option to participate in the co-develop...tor resulting from this collaboration. About sunesis Pharmaceuticals ...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO

...RANCISCO, Calif., May 26 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar... Additionally at the ASCO 2009 Annual Meeting, sunesis will be presenting clinical data on SNS-314, a nov...ll of these presentations will be available on the sunesis website at www.sunesis.com on the same day eac...

Sunesis Reports Financial Results for the First Quarter 2009

...FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today repo... Recent Highlights In April, sunesis announced the execution of a securities purchase a...acement, among other conditions. In April, sunesis presented data on voreloxin at the American Associ...

Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing

...ANCISCO, Calif., April 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...ate placement, and which is subject to approval by sunesis Pharmaceuticals' stockholders and the satisfaction...chievement of a specific milestone with respect to sunesis Pharmaceuticals' voreloxin product candidate and...

Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill

...such as Cephalon, Inc. [CEPH], Genentech, Inc. [DNA], Infinity Pharmaceuticals, Inc. [INFI], Memory Pharmaceuticals Corp., Pharmos Corporation [PARS], sunesis Pharmaceuticals, Inc. [SNSS] and Vertex Pharmaceuticals Incorporated [VRTX]. At this point, we believe that the Company's only legitimate option ...

Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference

...cess a webcast of the presentation by visiting the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

...cess a webcast of the presentation by visiting the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research

...ncer where topoisomerase II poisons are active." sunesis researchers conducted in vitro and cell-based stud...ancer. In a third set of studies reported today, sunesis researchers profiled the potential relationship be...sed previously in the treatment of cancer. About sunesis Pharmaceuticals ...
Sunesis in Medical Technology

SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

... SAN FRANCISCO , Dec. 7 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...erated. Conference Call Information sunesis management will host a conference call on Tuesday,...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

...NCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...60 Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

...SH," said Daniel Swisher, Chief Executive Officer, sunesis Pharmaceuticals. "Our goal is to advance voreloxin...been escalated to 75 mg/m2 dosed every four weeks. sunesis expects to complete enrollment of the 75 mg/m2 coh...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

...n an acute need for new treatment options. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...or the treatment of solid and hematologic cancers. sunesis has built a highly experienced cancer drug develop...

Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)

... In conjunction with this strategic restructuring, sunesis expanded the company's late-stage development lead...tently well tolerated in multiple clinical trials. sunesis is currently conducting Phase 2 clinical trials of...nation with cytarabine for the treatment of AML. sunesis continues ongoing trials in its earlier-stage clin...

Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting

...ofile demonstrated in this Phase 2 clinical trial, sunesis increased the dose of voreloxin in this trial to 6...een observed. Based on voreloxin's safety profile, sunesis recently announced that the protocol for the ongoi...25 percent to 75 mg/m(2) given once every 28 days. sunesis expects to enroll approximately 30 patients at thi...

Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress

...will be available following each conference on the sunesis corporate website at http://www.sunesis.com . About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...al in patients with advanced solid tumors. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia

...a from this trial indicate clear clinical benefit, sunesis could initiate a pivotal trial in this highly unde...medical conference toward the end of this year." sunesis previously reported promising results from its Pha...lerated weekly dose of 72 mg/m2 was established. sunesis also announced today that voreloxin has been accep...

Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research

...by the MMRC Validation Team, in collaboration with sunesis scientists, of SNS-032 in human myeloma cell lines...cell lymphoma cell lines" (Abstract #756). About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

More>>

Sunesis in Biological Technology

Sunesis Receives Approval for Listing on The NASDAQ Capital Market

...ANCISCO, Calif., July 30 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...ve at the opening of the market on August 3, 2009. sunesis will continue to trade under the symbol "SNSS." ...adhere to NASDAQ's corporate governance standards. sunesis requested the transfer of its listing based upon t...

Sunesis Reports Financial Results for the Second Quarter 2009

...ANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today repo... Recent Highlights In April, sunesis completed a $10.0 million initial closing of a tra...$8.8 million. The remaining units may be issued by sunesis upon the satisfaction of a clinical milestone and ...

Sunesis to Present at the Jefferies 3rd Annual Healthcare Conference

...ANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...cast of this presentation will be available on the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About...

Sunesis Pharmaceuticals Receives NASDAQ Notification

...NCISCO, Calif., April 17 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) reported t... by the Panel following the hearing. About sunesis Pharmaceuticals sunesis is a biopharmaceutical company focused on the deve...

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results

...ANCISCO, Calif., April 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today repo...s totaled $10.6 million, with no outstanding debt. sunesis Pharmaceuticals separately announced today the exe...d at all three dose levels. In March 2009, sunesis sold to SARcode Corporation all of the company's i...

Sunesis to Present at the 11th Annual BIO CEO & Investor Conference

...f the Sunesis website for two weeks. About sunesis Pharmaceuticals sunesis is a biopharmaceutical company focused on the deve...or the treatment of solid and hematologic cancers. sunesis has built a highly experienced cancer drug develop...

Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin

...ANCISCO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today prov...eloxin study in AML by the end of this year." sunesis is providing an update on the progress of its vore...Phase 2 and 1b/2 Studies of Voreloxin in AML sunesis is evaluating single agent voreloxin in an ongoing...

Sunesis to Present at Upcoming Conferences

...UTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...st of these presentations will be available on the sunesis website at http://ir.sunesis.com . A replay of t...ts" page in the Investors and Media section of the sunesis website for two weeks. About...

Sunesis to Present at Upcoming Conferences

...w and Lazard Capital presentations by visiting the sunesis website at http://ir.sunesis.com . A replay of th...tion of the Sunesis website for two weeks. About sunesis Pharmaceuticals sunesis is a biopharmaceutical company focused on the deve...

Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference

...cess a webcast of the presentation by visiting the sunesis website at http://ir.sunesis.com . A replay of th...ts" page in the Investors and Media section of the sunesis website for two weeks. About sunesis Pharmaceuticals ...
Other Tags
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... When head lice hits a home or school, parents ... rid of it while keeping it from taking over the ... the solution right in their neighborhood: Lice Troopers . ... full spectrum head lice screening and treatment services to families ... Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
(Date:12/25/2014)... December 25, 2014 Plugin creators from ... 5k. A fully customizable business presentation tool made specifically ... the ProFire 5k business tool, users can now display ... CEO of Pixel Film Studios. “ProFire 5k gives users ... to add professionalism to a presentation” , Pixel Film ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
Other Contents